Journal Article Research Support, Non-U.S. Gov't Ppublish 14 citations
PubMed: 30081294 DOI: 10.1016/j.jad.2018.07.062
Glycogen synthase kinase-3β genetic polymorphisms and insomnia in depressed patients: A prospective study.
J Affect Disord 240:230-236
Authors: Jean-François Costemale-Lacoste, Romain Colle, Séverine Martin, Khalil El Asmar, Emanuel Loeb, Bruno Feve, Céline Verstuyft, Séverine Trabado, Florian Ferreri, Emmanuel Haffen, Mircea Polosan, Laurent Becquemont, Emmanuelle Corruble
Affiliations
- CESP/UMR-S1178, Equipe "Dépression et Antidépresseurs", Univ Paris-Sud, Faculté de Médecine, INSERM, Le Kremlin Bicêtre, France; Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France; Dispositif Territorial de Recherche et Formation (DTRF) Paris Sud.
- CESP/UMR-S1178, Equipe "Dépression et Antidépresseurs", Univ Paris-Sud, Faculté de Médecine, INSERM, Le Kremlin Bicêtre, France; Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.
- CESP/UMR-S1178, Equipe "Dépression et Antidépresseurs", Univ Paris-Sud, Faculté de Médecine, INSERM, Le Kremlin Bicêtre, France.
- Sorbonne Universities, Pierre and Marie Curie University Paris 6, INSERM, Saint-Antoine Research Center, Saint-Antoine Hospital; Hospitalo-Universitary Institute, ICAN; Department of Endocrinology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris France; INSERM, UMR S_938- Centre de Recherche Saint-Antoine, Paris, France.
- CESP/UMR-S1178, Equipe "Dépression et Antidépresseurs", Univ Paris-Sud, Faculté de Médecine, INSERM, Le Kremlin Bicêtre, France; Service de Génétique Moléculaire, pharmacogénétique et hormonologie, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.
- Service de Génétique Moléculaire, pharmacogénétique et hormonologie, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.
- UPMC Paris 6; Department of Psychiatry, Saint-Antoine Hospital, Paris, France.
- Department of Clinical Psychiatry, University Hospital; EA 481, Laboratory of Neurosciences, University of Bourgogne Franche-Comté; CIC-1431 Inserm, University Hospital, Besançon, France.
- Univ. Grenoble Alpes; Inserm U1216, Grenoble Institut de Neurosciences, CHU de Grenoble, F-38000 Grenoble, France.
- CESP/UMR-S1178, Equipe "Dépression et Antidépresseurs", Univ Paris-Sud, Faculté de Médecine, INSERM, Le Kremlin Bicêtre, France; Centre de Recherche Clinique Paris Sud, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France.
- CESP/UMR-S1178, Equipe "Dépression et Antidépresseurs", Univ Paris-Sud, Faculté de Médecine, INSERM, Le Kremlin Bicêtre, France; Service Hospitalo-Universitaire de Psychiatrie de Bicêtre, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, Le Kremlin Bicêtre, France; Dispositif Territorial de Recherche et Formation (DTRF) Paris Sud.
Abstract
BACKGROUND
80-90% of patients with Major Depressive Episode (MDE) experience insomnia and up-to 50% severe insomnia. Glycogen Synthase Kinase-3β (GSK3B) is involved both in mood regulation and circadian rhythm. Since GSK3B polymorphisms could affect protein levels or functionality, we investigated the association of GSK3B polymorphisms with insomnia in a sample of depressed patients treated with antidepressants.
METHODS
In this 6-month prospective real-world treatment study in psychiatric settings (METADAP), 492 Caucasian patients requiring a new antidepressant treatment were included and genotyped for five GSK3B Single Nucleotide Polymorphisms (SNPs) (rs6808874, rs6782799, rs2319398, rs13321783, rs334558). Insomnia and MDE severity were rated using the Hamilton Depression Rating Scale (HDRS). Bi- and multivariate analyses were performed to assess the association between GSK3B SNPs and insomnia (main objective). We also assessed their association with MDE severity and HDRS response/remission after antidepressant treatment.
RESULTS
At baseline severe insomnia was associated with the GSK3B rs334558 minor allele (C+) [OR=1.81, CI95%(1.17-2.80), p=0.008]. GSK3B rs334558 C+ had greater insomnia improvement after 6 months of antidepressant treatment (p=0.007, β=0.17, t=2.736). No association was found between GSK3B SNPs and MDE baseline severity or 6-month response/remission.
CONCLUSION
GSK3B rs334558 was associated with insomnia but not with MDE severity in depressed patients. Targeting GSK3B in patients with MDE and a severe insomnia could be a way to improve their symptoms with greater efficiency. And it should be further studied whether the GSK3B-insomnia association may fit into the larger picture of mood disorders.
MeSH
Affective Symptoms, Sleep Initiation And Maintenance Disorders, Antidepressive Agents, Prospective Studies, Polymorphism, Genetic, Polymorphism, Single Nucleotide, Glycogen Synthase Kinases
Cited by
- Rapid-acting antidepressants and the circadian clock. Neuropsychopharmacology, 2022
- Molecular targets and mechanisms involved in the action of Banxia Shumi decoction in insomnia treatment. Medicine (Baltimore), 2023
- Implications of neurogenesis in depression through BDNF: rodent models, regulatory pathways, gut microbiota, and potential therapy. Mol Psychiatry, 2025
- Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward. Front Mol Neurosci, 2022
- Genetic endophenotypes for insomnia of major depressive disorder and treatment-induced insomnia. J Neural Transm (Vienna), 2020
- Interactions Between Glycogen Synthase Kinase-3β Gene Polymorphisms, Negative Life Events, and Susceptibility to Major Depressive Disorder in a Chinese Population. Front Psychiatry, 2021